Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence : A population-based cohort study in the five nordic countries.
To assess the risk of subsequent malignant neoplasms among Hodgkin's disease patients diagnosed before 20 years of age in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).
Patients and Methods
There were 1,641 Hodgkin's disease patients identified through the national cancer registries since the 1940s or 1950s.
The patients were monitored for 17,000 person-years until the end of 1991.
Expected figures were derived from the age-specific incidence rates in each country and standardized incidence ratios (SIR) were calculated.
A total of 62 subsequent neoplasms were diagnosed (SIR, 7.7 ; 95% confidence interval [CI], 5.9 to 9.9).
The overall cumulative risk of subsequent neoplasms was 1.9% at the 10-year follow-up point, 6.9% at 20 years, and 18% at 30 years.
There were 26 subsequent neoplasms among males (SIR, 6.5 ; 95% Cl, 4.3 to 9.6) and 36 among females (SIR, 8.9 ; 95% Cl, 6.2 to 12), of which 16 were breast cancers (SIR, 17 ; 95% Cl, 9.9 to 28).
High risks were seen for thyroid cancer (SIR, 33 ; 95% Cl, 15 to 62), for secondary leukemia (SIR, 17 ; 95% Cl, 6.9 to 35), and for non-Hodgkin's lymphoma (SIR, 15 ; 95% Cl, 4.9 to 35).
The relative risk increased from 3.3 (95% Cl, 1.2 to 7.1) for Hodgkin's disease patients diagnosed in the 1940s and 1950s to 15 (95% Cl, 7.4 to 27) in the 1980s.
The highest risk of secondary leukemia (SIR, 68 ; 95% Cl, 18 to 174) was seen among those diagnosed with Hodgkin's disease i...
Mots-clés Pascal : Hodgkin maladie, Enfant, Homme, Adolescent, Second cancer, Epidémiologie, Analyse risque, Incidence, Etude cohorte, Pays Scandinaves, Europe, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome, Tumeur maligne
Mots-clés Pascal anglais : Hodgkin disease, Child, Human, Adolescent, Second cancer, Epidemiology, Risk analysis, Incidence, Cohort study, Scandinavia, Europe, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0255386
Code Inist : 002B04B. Création : 199608.